<DOC>
	<DOC>NCT00304980</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of sulfadoxine-pyrimethamine (SP) versus artemether-lumefantrine (Coartem) when administered to HIV+ and HIV- patients with uncomplicated P. falciparum malaria. Patients will be randomised to one of the 2 treatment and followed up (until day 14 actively) for 45 days.</brief_summary>
	<brief_title>Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria, Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Man and nonpregnant women aged between 15 and 50. P.falciparum monoinfection of at least 1,000 parasites/µl. Body temperature ≥ 37.5°C at the moment of enrolment or history of fever in the preceding 48 hrs. Consent from patient obtained. Pregnancy. Severe P. falciparum malaria . Documented intake of SP or Coartem two weeks or less prior recruitment. Other cause(s) of fever. Evidence of underlying chronic diseases (cardiac, renal, hepatic, malnutrition). History of allergy to study drug, or known allergy to other Sulphur drugs such as cotrimoxazol.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>